New and updated preclinical and clinical data presented by biopharma firms at the European Hematology Association Congress, including: Actinium, Aptose, Cellectis, Disc, Geron, Gracell, Humanigen, Innate, Innovent, Kura, Modus, Nkarta, Salarius, Sumitomo.
Disc Medicine Inc.’s positive phase II data from an ongoing, open-label trial called Beacon with oral bitopertin in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) whetted investor appetite for the results of the other mid-stage Disc experiment known as Aurora with the compound, due early next year.
Daiichi Sankyo Co. Ltd.’s quizartinib met the primary endpoint of overall survival in the pivotal phase III Quantum-First study, which tested the addition of quizartinib to chemotherapy vs. chemotherapy alone for adults with newly diagnosed FLT3-ITD-positive acute myeloid leukemia (AML).